Hans Edgar Bishop - 21 Jun 2021 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Director
Signature
/s/ Heather Turner, as Attorney-in-fact
Issuer symbol
LYEL
Transactions as of
21 Jun 2021
Net transactions value
$0
Form type
4
Filing time
23 Jun 2021, 17:35:22 UTC
Previous filing
16 Jun 2021
Next filing
25 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Conversion of derivative security +546,806 +18% 3,546,806 21 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Series A Convertible Preferred Stock Conversion of derivative security $0 -546,806 -100% $0.000000* 0 21 Jun 2021 Common Stock 546,806 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date.